Pharmaceutical Market Europe • February 2026 • 41
APPOINTMENTS
Accord Healthcare
Accord Healthcare has appointed Paul Burden as Associate Vice President and Country Head UK. Burden brings over 26 years of pharmaceutical experience to the role and has worked in both the UK and European pharmaceutical industries. His expertise in leading commercial strategy and building high-performing teams to drive growth encompasses both generics and speciality pharmaceuticals. He most recently served as Vice President of STADA, a role that saw him overseeing strategy and execution for established brands as well as generics and speciality pharmaceuticals. Burden also previously held multiple senior leadership roles, such as Chief Commercial Officer Europe and President UK & Ireland, at ADVANZ PHARMA. Other companies where Burden has held roles include Teva, Mylan and Novartis.
Alvotech
Lisa Graver
Alvotech has appointed Lisa Graver as CEO. Prior to its acquisition by Lotus Pharmaceutical in 2025, Graver served as CEO of Alvogen, where she worked for over 15 years in roles including President and Executive Vice President. She was also previously Vice President, Intellectual Property at Actavis Switzerland and Innovest Enterprises.
Vibrant Therapeutics
Han Lee
Vibrant Therapeutics has appointed Han Lee as co-CEO. Lee brings over 15 years of expertise in leadership to his new role at Vibrant, having most recently served as President and Chief Financial Officer of ImmPACT Bio. Previously, Lee led Corporate Development and Ventures at AstraZeneca, including financings, mergers, acquisitions and partnerships.
Rentschler Biopharma
Uwe Buecheler
Rentschler Biopharma has appointed Uwe Buecheler as interim CEO. He has served as Vice Chairman of the Supervisory Board at Rentschler since 2024, and also currently serves as Non-Executive Director at BioPhorum. He previously spent over 33 years at Boehringer Ingelheim, in roles including Senior Vice President Head of Business Unit Biopharmaceuticals.
THX Pharma
Julien Veys
THX Pharma has appointed Julien Veys as Deputy CEO. Veys has served at THX since 2016 in positions including Chief Business Development Officer and Chief Operating Officer. Prior to this, he spent over a decade at Trophos, serving as Chief Business Development Officer as well as a variety of other roles.
iOrganBio
Karol Jarzabek
iOrganBio has appointed Karol Jarzabek as Chief Operating Officer. Jarzabek most recently served as Vice President of Portfolio Operations at QHP Capital. Prior to his time at QHP, Jarzabek held a series of senior leadership positions at Azurity Pharmaceuticals, including Vice President of Strategic Finance and President of Established Brands.
GC Therapeutics
Kate Haviland
GC Therapeutics has appointed Kate Haviland as Board Chair. Haviland was most recently President and CEO of Blueprint Medicines, where she also previously held the roles of Chief Operating Officer and Chief Business Officer prior to the company’s 2025 acquisition by Sanofi. She has also served at Idera Pharmaceuticals, Sarepta Therapeutics and Genzyme.
AstronauTx
Adam Rosenberg
AstronauTx has appointed Adam Rosenberg as Board Chair. Rosenberg currently serves as CEO of RyCarma Therapeutics, and has formerly held the role of CEO at Aliada Therapeutics, Athenen Therapeutics, Link Medicine, Rodin Therapeutics and Teleos Therapeutics. He also previously founded Sionna Therapeutics, where he held the role of CEO.
Cumulus Neuroscience
Ricardo Sáinz Fuertes
Cumulus Neuroscience has appointed Ricardo Sáinz Fuertes as Board Chair. Sáinz Fuertes brings more than a decade of pharmaceutical industry experience to his new position. He has held the role of Global Director of Digital Health Solutions at Eisai since 2023, and is an Honourary Clinical Fellow of the University of Edinburgh.